AKT1 and neuroblastoma: In fact, CMap analysis identified PI3K/Akt/mTOR inhibitors as potentially suitable candidate compounds for NB treatment, because they were able to revert the expression of genes in different cancer cell lines that we previously found to be associated with hypoxia in NB patients.